The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Although early reports suggested that COVID-19-associated ARDS has distinctive features that set it apart from historical ARDS, emerging evidence indicates that the respiratory system mechanics of patients with ARDS, with or without COVID-19, are broadly similar.
https://www.theguardian.com/world/2020/oct/15/long-covid-what-we-know-so-far
Permanent organ damage to lungs and heart!
https://www.bbc.co.uk/news/health-54540544
I’m not too bothered either about what inhaler they are using but love the fact that NodThera updated their shareholders that they are.....
Its most advanced inhibitor, NT-0167, is under evaluation in a Phase 1 clinical trial in healthy volunteers.
It’s just nice getting that extra info which helps us I suppose
https://www.bbc.co.uk/news/health-54296223
Acute respiratory distress syndrome
NFX have started to review and assess some emerging academic data that suggest coronaviruses can trigger hyper-inflammation through activation of the biological target known as the NLRP3 inflammasome, making this a potential novel drug target to treat COVID-19. The mechanism of NXP002 can interact directly with NLRP3, blocking the assembly of the inflammasome. This still requires clinical validation, we intend to explore the commercial potential of this attribute of our drug.
Long Covid could be bigger public health issue than excess deaths, academic warns
https://www.itv.com/news/2020-10-05/long-covid-could-be-bigger-public-health-issue-than-excess-deaths-academic-warns